We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: dulaglutide
MedXY News
EnglishTag

dulaglutide

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Dulaglutide Versus Insulin in Adolescents With Thalassaemia-Induced Diabetes: Improving Glycaemic Control and Metabolic Health in a High-Risk Population
Diabetes & Endocrinologyglycaemic variabilitythalassaemia-induced diabetes

Dulaglutide Versus Insulin in Adolescents With Thalassaemia-Induced Diabetes: Improving Glycaemic Control and Metabolic Health in a High-Risk Population

By MedXY|Aug 21, 2026

The DIADEMA trial demonstrates dulaglutide’s superiority over insulin in improving glycaemic variability, pancreatic function, and iron overload, without safety concerns, in adolescents with thalassaemia-induced diabetes.

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit
Cardiology
cardiorenal outcomes
dulaglutide

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit

By MedXY|Jun 19, 2026

Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT
Diabetes & Endocrinologyalbuminuriachronic kidney disease

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT

By MedXY|May 12, 2026

In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Clinical UpdatesdulaglutideEcnoglutide

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

By MedXY|Oct 8, 2025

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities